Anupam Rasayan launches ₹829 Crore Open Offer for Bliss GVS Pharma

Anupam Rasayan India Limited's open offer to acquire 26% of Bliss GVS Pharma Limited’s expanded voting share capital at ₹299 per share is valued at ₹829.03 crore.

Reader Takeaway: Offers shareholders an exit at a premium; conditional deal completion and regulatory approvals are key.

What just happened

Anupam Rasayan India Limited has triggered a mandatory open offer for Bliss GVS Pharma Limited. This follows Anupam Rasayan's agreement to purchase 4.58 crore equity shares, representing 43.30% of Bliss GVS Pharma's equity, from promoters and other shareholders. The offer price is ₹299 per share, and the total consideration for the open offer, assuming full acceptance, is ₹829.03 crore. Anupam Rasayan stated it does not intend to delist Bliss GVS Pharma.

Why this matters

This is a significant M&A event for Bliss GVS Pharma shareholders. The open offer provides a clear exit opportunity at a premium price of ₹299 per share. For Anupam Rasayan, it signifies strategic expansion. Both companies have reported robust financial growth in their projected FY26 and FY25 results, suggesting operational strength.

The backstory

Anupam Rasayan India Limited, a custom synthesis and specialty chemical manufacturer, is expanding its footprint. Bliss GVS Pharma Limited operates in the pharmaceutical sector. The current transaction is driven by Anupam Rasayan's acquisition of a substantial stake from existing shareholders.

What changes now

Public shareholders of Bliss GVS Pharma can choose to tender their shares during the offer period, which runs from July 16, 2026, to July 29, 2026. Anupam Rasayan intends to support Bliss GVS Pharma's management and growth strategies, though it reserves the right to restructure operations if needed.

Risks to watch

The transaction is conditional. Its completion depends on satisfying certain conditions precedent outlined in the Share Purchase Agreement. There is also a regulatory risk concerning the acquisition of necessary statutory approvals. Offer withdrawal is possible if these conditions or approvals are not met.

Peer comparison

Anupam Rasayan India Limited is primarily in the specialty chemicals sector. Bliss GVS Pharma operates in the pharmaceutical industry. This is an acquisition by a specialty chemical company into the pharma space, indicating diversification or strategic alignment in healthcare-related products.

Context metrics (time-bound)

• Anupam Rasayan (Acquirer) Financials: Revenue from operations grew 64.6% to ₹2,365.45 crore in FY26 (projected). Profit After Tax rose 38.9% to ₹222.20 crore in FY26 (projected).
• Bliss GVS Pharma (Target) Financials: Revenue from operations grew 14.5% to ₹927.11 crore in FY26 (projected). Profit After Tax surged 49.3% to ₹134.73 crore in FY26 (projected).
• Open Offer Period: July 16, 2026, to July 29, 2026.

What to track next

Investors should closely follow the official announcements regarding the open offer process, including any updates on conditions precedent and regulatory approvals. Monitoring the acceptance ratio during the tendering period will be crucial for shareholders.